COMPANY ANNOUNCEMENT

Valby, Denmark, 17 September 2026

Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.

In connection with the voluntary exchange offer to eligible shareholders in Lundbeck, the Lundbeck Foundation (via its fully owned subsidiary Lundbeckfond Invest A/S) (the Foundation) offered eligible shareholders a 1:1 exchange of their A-shares with the Lundbeck Foundation's B-shares.
In accordance with Article 19 of Regulation No. 596/2014 on market abuse, Lundbeck is required to report transactions made by executives and their closely associated parties. This includes the number of shares exchanged.

Following the completion of the exchange offer, the Foundation now holds approximately 92% of the A shares and approximately 63% of the B-shares. The total share capital held by the Foundation is approximately 69% and the total voting rights held by the Foundation in Lundbeck is approximately 84%.

1.	**Details of the person discharging managerial responsibilities / person closely associated**	
a)	Name	Lundbeckfond Invest A/S
2.	**Reason for the notification**	
a)	Position/status	Closely associated party due to Lene Skole-Sørensen's capacity as Deputy Chair of H. Lundbeck A/S and CEO of Lundbeckfond Invest A/S as well as due to Lars Erik Holmqvist's capacity as member of the board of directors of H. Lundbeck A/S and Deputy Chair of Lundbeckfond Invest A/S.
b)	Initial notification/Amendment	Initial notification
3.	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a)	Name	H. Lundbeck A/S
b)	LEI code	5493006R4KC2OI5D3470
4.	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**	
a)	Description of the financial instrument, type of instrument Identification code	Shares DK0061804697 (A-shares)

		DK0061804770 (B-shares)	
b)	Nature of the transaction	Exchange of shares. The volume number indicated below is the number of Lundbeckfond Invest A/S' B-shares exchanged in return for other shareholders' A-shares at a 1:1 basis.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 41.78	23,666,150
d)	Aggregated information - Aggregated volume - Price	Aggregated volume: 23,666,150 Aggregated price of the transaction: DKK 988,771,747.	
e)	Date of the transaction	2026-09-16	
f)	Place of the transaction	Outside a trading venue	

1.	**Details of the person discharging managerial responsibilities / person closely associated**		
a)	Name	Ilse Dorothea Wenzel	
2.	**Reason for the notification**		
a)	Position/status	Chair of the Board of Directors	
b)	Initial notification/Amendment	Initial notification	
3.	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**		
a)	Name	H. Lundbeck A/S	
b)	LEI code	5493006R4KC2OI5D3470	
4.	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**		
a)	Description of the financial instrument, type of instrument Identification code	Shares DK0061804697 (A-shares) DK0061804770 (B-shares)	
b)	Nature of the transaction	Exchange of shares. The volume number indicated below is the number of A-shares exchanged in return for B-shares at a 1:1 basis.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 39.35	45,000
d)	Aggregated information - Aggregated volume - Price	Aggregated volume: 45,000 Aggregated price of the transaction: DKK 1.770.750.	
e)	Date of the transaction	2026-09-16	
f)	Place of the transaction	Outside a trading venue	

Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities mean inter alia:

- spouse or cohabitant
- dependent children
- legal entities in which the executive has a controlling influence.

Contacts

Jens Høyer
Vice President, Head of Investor Relations
JSHR@lundbeck.com
+45 30 83 45 01

Anders Crillesen
Senior Director, External & Internal Relations
AECE@lundbeck.com
+45 27 79 12 86

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.